AstraZeneca (AZN) Stock Forecast & Price Target $72.66 +0.06 (+0.08%) As of 10:20 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating BuyBased on 10 Analyst RatingsSell0Hold1Buy9 Based on 10 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 1 has given a hold rating, 7 have given a buy rating, and 2 have given a strong buy rating for AZN. Consensus Price Target $89.7523.52% Upside According to the 10 analysts' twelve-month price targets for AstraZeneca, the average price target is $89.75. The highest price target for AZN is $97.00, while the lowest price target for AZN is $82.00. The average price target represents a forecasted upside of 23.52% from the current price of $72.66. Get the Latest News and Ratings for AZN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors. Enter your email to sign up for newsletter Sign Up AZN Analyst Ratings Over TimeTypeCurrent Forecast4/2/24 to 4/2/251 Month Ago3/3/24 to 3/3/253 Months Ago1/3/24 to 1/2/251 Year Ago4/3/23 to 4/2/24Strong Buy2 Strong Buy rating(s)2 Strong Buy rating(s)2 Strong Buy rating(s)0 Strong Buy rating(s)Buy7 Buy rating(s)7 Buy rating(s)6 Buy rating(s)3 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)3 Hold rating(s)2 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)1 Sell rating(s)Consensus Price Target$89.75$89.75$89.75$80.00Forecasted Upside23.52% Upside17.94% Upside36.23% Upside19.40% UpsideConsensus RatingBuyBuyModerate BuyHold Remove Ads AZN Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History AZN Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table AstraZeneca Stock vs. The CompetitionTypeAstraZenecaMedical CompaniesS&P 500Consensus Rating Score 3.10 2.82 2.54Consensus RatingBuyModerate BuyModerate BuyPredicted Upside23.62% Upside19,861.64% Upside19.01% UpsideNews Sentiment RatingPositive NewsSee Recent AZN NewsPositive NewsPositive News Remove Ads Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails2/13/2025UBS Group4 of 5 starsM. WestonSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy2/12/2025Morgan Stanley3 of 5 stars Initiated CoverageOverweight11/6/2024Deutsche Bank Aktiengesellschaft3 of 5 stars UpgradeSell ➝ Hold9/11/2024Erste Group BankSubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeHold ➝ Buy8/12/2024TD CowenSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$90.00 ➝ $95.00+16.29%6/24/2024CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingP. VerdultSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/24/2024BarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingE. FieldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/30/2024ArgusSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$80.00 ➝ $85.00+10.72%5/30/2024The Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuy$97.00+27.50%4/26/2024BMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetOutperform ➝ Outperform$80.00 ➝ $82.00+8.70%1/3/2024Jefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeBuy ➝ Hold12/18/2023HSBCSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuyAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:20 AM ET. Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, March 31, 2025. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com. AstraZeneca Bull Case Here are some ways that investors could benefit from investing in AstraZeneca: AstraZeneca has received multiple upgrades from analysts, including a recent upgrade from UBS Group from "neutral" to "buy," indicating strong market confidence in the company's future performance. The stock currently trades at approximately $73.79, reflecting a solid market capitalization of around $228.84 billion, which suggests a stable investment opportunity. Recent institutional investments show a growing interest in AstraZeneca, with Foundation Wealth Management LLC acquiring 38,376 shares, indicating confidence from significant investors. The company has a consensus rating of "Buy" from analysts, with a target price of $89.75, suggesting potential for price appreciation. AstraZeneca's diverse portfolio of products, including recent advancements in pharmaceuticals, positions it well for future growth in the healthcare sector. AstraZeneca Bear Case Investors should be bearish about investing in AstraZeneca for these reasons: GQG Partners LLC recently reduced its holdings in AstraZeneca by 20.1%, which may signal a lack of confidence from some institutional investors. The stock has experienced fluctuations, with a 12-month low of $62.75, indicating potential volatility that could concern risk-averse investors. Despite positive analyst ratings, the company faces significant competition in the pharmaceutical industry, which could impact its market share and profitability. The current debt-to-equity ratio of 0.65 suggests that AstraZeneca has a moderate level of debt, which could pose risks if market conditions change. Market conditions and regulatory challenges in the healthcare sector can create uncertainties that may affect AstraZeneca's performance and stock price. AZN Forecast - Frequently Asked Questions What is AstraZeneca's forecast for 2025? According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is $89.75, with a high forecast of $97.00 and a low forecast of $82.00. Should I buy or sell AstraZeneca stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There is currently 1 hold rating, 7 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AZN shares. Does AstraZeneca's stock price have much upside? According to analysts, AstraZeneca's stock has a predicted upside of 23.52% based on their 12-month stock forecasts. Has AstraZeneca been upgraded by Wall Street analysts recently? Over the previous 90 days, AstraZeneca's stock had 1 upgrade by analysts. What analysts cover AstraZeneca? AstraZeneca has been rated by research analysts at Morgan Stanley, and UBS Group in the past 90 days. Do Wall Street analysts like AstraZeneca more than its competitors? Analysts like AstraZeneca more than other "medical" companies. The consensus rating for AstraZeneca is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AZN compares to other companies. Stock Forecasts and Research Tools Related Companies NVO Stock Forecast NVS Stock Forecast SNY Stock Forecast GSK Stock Forecast ARGX Stock Forecast ONC Stock Forecast BNTX Stock Forecast TEVA Stock Forecast SMMT Stock Forecast ITCI Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:AZN) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AZN Stock Free AZN Stock Alerts